7 results about "Diphtheria" patented technology

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention provides an attenuated pertussis CS recombinant bacterium, the CS recombinant bacterium is obtained by mutating a ninth arginine residue of an S1 subunit in a CS strain with a preservation number of CMCC 58003 into a lysine residue and mutating a 129th glutamic acid residue into a glycine residue, and the amino acid sequence of the S1 subunit of the CS recombinant bacterium is as shown in SEQ ID NO.1. The invention further provides a preparation method of the attenuated pertussis CS recombinant bacterium. The method for constructing the recombinant bacteria comprises the following steps: constructing recombinant plasmids; preparing competent cells of the wild pertussis CS strain; electrically transferring the recombinant plasmid into competent cells of the wild pertussis CS strain; respectively preparing BG sheep blood screening plates containing Amp and DOG; sequentially screening a first round and a second round of recombinant pertussis CS strains; and preparing the two-round recombinant pertussis CS strain into a competent strain, and screening twice according to the same steps to obtain the attenuated pertussis CS recombinant strain. The constructed recombinant bacteria can efficiently obtain detoxified PT, and can be applied to products for treating, detecting and preventing pertussis diseases.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The present disclosure is directed to fusion proteins and propeptide fusions comprising a diphtheria toxin catalytic domain and translocation domain with a receptor binding domain from a Clostridial neurotoxin. The fusion protein has a therapeutic cargo positioned upstream of the catalytic domain. Also disclosed are therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins.

The application discloses a preparation method and application of a cocktail vaccine of Acinetobacter baumannii, and belongs to the technical field of vaccine preparation. The vaccine comprises sugar conjugates formed by coupling three branched pentasaccharides of K14, K47 and K128 with diphtheria toxoid. The preparation method comprises the steps of hapten synthesis, purification, coupling with carrier protein and mixing. Experiments show that the vaccine can induce high levels of specific antibodies, significantly reduce the tissue bacterial load of mice infected with Acinetobacter baumannii, and has a wide protective effect. The application is suitable for preventing and treating various infectious diseases caused by Acinetobacter baumannii.

The invention discloses a pathogen infection diagnosis marker based on DPH gene family mRNA and diphtheria amide modification level, a kit and application. The marker combination comprises the mRNA expression level of the DPH1-DPH7 gene and the diphtheria amide modification level of the eukaryotic elongation factor 2. The invention reveals that the combination is remarkably related to pathogen infection for the first time, and provides a detection kit containing a specific primer, biotinylated NAD, pseudomonas exotoxin A and other reagents. The indexes are respectively detected through qPCR (quantitative polymerase chain reaction) and non-denatured immunoblotting, and efficient diagnosis can be realized through combined analysis. Experiments show that the combined marker is excellent in diagnostic performance, the area AUC under a curve of a combined logistic regression model can reach 0.917, the sensitivity is 90.9%, the specificity is 85.7%, and a novel and reliable molecular scheme is provided for early-stage differential diagnosis of infection.

The present invention relates to a process of purifying a protein. Specifically, the present invention relates to a process of purification of a polyclonal antibody and / or antibody fragments. The present invention employs an adsorptive separation using anion exchange chromatography and cation exchange chromatography along with ultrafiltration and diafiltration to achieve high-purity antibody / or antibody fragments. The process provided in the present invention is applicable for polyclonal antibody and / or antibody fragments, which are associated with conditions but not limited to snake envenomation, scorpion envenomation, diphtheria infection, tetanus infection, rabies virus infection and gas gangrene infection due to Clostridium species.